141 related articles for article (PubMed ID: 20592383)
1. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.
Rack B; Jückstock J; Genss EM; Schoberth A; Schindlbeck C; Strobl B; Heinrigs M; Rammel G; Zwingers T; Sommer H; Friese K; Janni W
Anticancer Res; 2010 May; 30(5):1807-13. PubMed ID: 20592383
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
Rack B; Schindlbeck C; Strobl B; Sommer H; Friese K; Janni W
Dtsch Med Wochenschr; 2008 Feb; 133(7):285-9. PubMed ID: 18253918
[TBL] [Abstract][Full Text] [Related]
3. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.
Janni W; Rack B; Schindlbeck C; Strobl B; Rjosk D; Braun S; Sommer H; Pantel K; Gerber B; Friese K
Cancer; 2005 Mar; 103(5):884-91. PubMed ID: 15666325
[TBL] [Abstract][Full Text] [Related]
4. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.
Wiedswang G; Borgen E; Kåresen R; Qvist H; Janbu J; Kvalheim G; Nesland JM; Naume B
Clin Cancer Res; 2004 Aug; 10(16):5342-8. PubMed ID: 15328170
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
6. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.
Wiedswang G; Borgen E; Kåresen R; Kvalheim G; Nesland JM; Qvist H; Schlichting E; Sauer T; Janbu J; Harbitz T; Naume B
J Clin Oncol; 2003 Sep; 21(18):3469-78. PubMed ID: 12972522
[TBL] [Abstract][Full Text] [Related]
7. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients.
Solomayer EF; Diel IJ; Salanti G; Hahn M; Gollan C; Schütz F; Bastert G
Clin Cancer Res; 2001 Dec; 7(12):4102-8. PubMed ID: 11751508
[TBL] [Abstract][Full Text] [Related]
8. [The influence of the hemoglobin concentration on the hematogenous tumor cell dissemination at the time of the initial diagnosis of breast cancer].
Janni W; Strobl B; Rack B; Rjosk D; Schindlbeck C; Hantschmann P; Kentenich C; Sigg W; Zerzer M; Sommer H
Dtsch Med Wochenschr; 2002 Jan; 127(3):71-7. PubMed ID: 11797143
[TBL] [Abstract][Full Text] [Related]
9. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
von Minckwitz G; Rezai M; Tesch H; Huober J; Gerber B; Zahm DM; Hilfrich J; Costa SD; Dubsky P; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Fasching PA; Schneeweiss A; Paepke S; Untch M; Burchardi N; Mehta K; Loibl S;
Eur J Cancer; 2016 Sep; 64():12-21. PubMed ID: 27323347
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
[TBL] [Abstract][Full Text] [Related]
12. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
[TBL] [Abstract][Full Text] [Related]
13. Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed.
Wiedswang G; Borgen E; Karesen R; Naume B
Cytotherapy; 2003; 5(1):40-5. PubMed ID: 12745581
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
16. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.
Becker S; Becker-Pergola G; Wallwiener D; Solomayer EF; Fehm T
Breast Cancer Res Treat; 2006 May; 97(1):91-6. PubMed ID: 16319975
[TBL] [Abstract][Full Text] [Related]
17. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
18. Articular damage is associated with intraosseous inflammation in the subchondral bone marrow of joints affected by experimental inflammatory arthritis and is modified by zoledronate treatment.
Bogoch ER; Lee TC; Fornasier VL; Berger SA
J Rheumatol; 2007 Jun; 34(6):1229-40. PubMed ID: 17516617
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
20. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
